Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)
Restricted accessResearch articleFirst published online October, 2023
Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS)
Colchicine has a narrow therapeutic index. Its toxicity can be increased due to concomitant exposure to drugs inhibiting its metabolic pathway; these are cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp).
Objective:
To examine clinical outcomes associated with colchicine drug interactions using the spontaneous reports of the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS).
Methods:
We conducted a disproportionality analysis using FAERS data from January 2004 through June 2020. The reporting odds ratio (ROR) and observed-to-expected ratio (O/E) with shrinkage for adverse events related to colchicine’s toxicity (ie, rhabdomyolysis/myopathy, agranulocytosis, hemorrhage, acute renal failure, hepatic failure, arrhythmias, torsade de pointes/QT prolongation, and cardiac failure) were compared between FAERS reports.
Results:
A total of 787 reports included the combined mention of colchicine, an inhibitor of both CYP3A4 and P-gp drug, and an adverse event of interest. Among reports that indicated the severity, 61% mentioned hospitalization and 24% death. A total of 37 ROR and 34 O/E safety signals involving colchicine and a CYP3A4/P-gp inhibitor were identified. The strongest ROR signal was for colchicine + atazanavir and rhabdomyolysis/myopathy (ROR = 35.4, 95% CI: 12.8-97.6), and the strongest O/E signal was for colchicine + atazanavir and agranulocytosis (O/E = 3.79, 95% credibility interval: 3.44-4.03).
Conclusion and Relevance:
This study identifies numerous safety signals for colchicine and CYP3A4/P-gp inhibitor drugs. Avoiding the interaction or monitoring for toxicity in patients when co-prescribing colchicine and these agents is highly recommended.
RodnanGPBenedekTG.The early history of antirheumatic drugs. Arthritis Rheum. 1970;13(2):145-165. doi:10.1002/art.1780130207
3.
BhatANaguwaSMCheemaGSGershwinME.Colchicine revisited. Ann N Y Acad Sci. 2009;1173(1):766-773. doi:10.1111/j.1749-6632.2009.04674.x
4.
HemkensLGEwaldHGloyVL, et al. Cardiovascular effects and safety of long-term colchicine treatment: Cochrane review and meta-analysis. Heart. 2016;102(8):590-596. doi:10.1136/heartjnl-2015-308542
5.
DasgebBKornreichDMcGuinnKOkonLBrownellISackettDL.Colchicine: an ancient drug with novel applications. Br J Dermatol. 2018;178(2):350-356. doi:10.1111/bjd.15896
6.
ImaiSMomoKKashiwagiHMiyaiTSugawaraMTakekumaY.Prescription of colchicine with other dangerous concomitant medications: a nation-wide survey using the Japanese claims database. Biol Pharm Bull. 2020;43(10):1519-1525. doi:10.1248/bpb.b20-00314
7.
DixonDLPatelJSpenceRTalasazAHAbbateAWigginsBS.Select drug-drug interactions with colchicine and cardiovascular medications: a review. Am Heart J. 2022;252:42-50. doi:10.1016/j.ahj.2022.06.002
8.
FinkelsteinYAksSEHutsonJR, et al. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol (Phila). 2010;48(5):407-414. doi:10.3109/15563650.2010.495348
9.
AndreisAImazioMAvondoS, et al. Adverse events of colchicine for cardiovascular diseases: a comprehensive meta-analysis of 14 188 patients from 21 randomized controlled trials. J Cardiovasc Med. 2021;22(8):637-644. doi:10.2459/JCM.0000000000001157
10.
StewartSYangKCKAtkinsKDalbethNRobinsonPC.Adverse events during oral colchicine use: a systematic review and meta-analysis of randomised controlled trials. Arthritis Res Ther. 2020;22(1):28. doi:10.1186/s13075-020-2120-7
AkdagIErsoyAKahveciogluSGulluluMDilekK.Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure. J Nephrol. 2006;19(4):515-517.
13.
ChengVCHoPLYuenKY.Two probable cases of serious drug interaction between clarithromycin and colchicine. South Med J. 2005;98(8):811-813. doi:10.1097/01.SMJ.0000163315.02563.B2
14.
TerkeltaubRAFurstDEDigiacintoJLKookKADavisMW.Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis Rheum. 2011;63(8):2226-2237. doi:10.1002/art.30389
Girard de CourtillesMBalussonFQuericC, et al. Interactions médicamenteuses avec la colchicine, les contre-indications sont-elles bien respectées ? Étude descriptive des prescriptions en Bretagne à partir des données de l’Assurance maladie. Therapies. 2020;75(6):675-679. doi:10.1016/j.therap.2020.06.003
17.
Olmos-MartínezJMMolinaHSalasCOlmosJMHernándezJL.Acute colchicine-induced neuromyopathy in a patient treated with atorvastatin and clarithromycin. Eur J Case Rep Intern Med. 2019;6(3):001066. doi:10.12890/2019_001066
18.
SabanisNPaschouEDrylliAPapanikolaouPZagkotsisG.Rosuvastatin and Colchicine combined myotoxicity: lessons to be learnt. CEN Case Rep. 2021;10(4):570-575. doi:10.1007/s13730-021-00598-7
19.
SoutyCLaunayTSteichenO, et al. Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions. Eur J Clin Pharmacol. 2020;76(12):1675-1682. doi:10.1007/s00228-020-02952-7
20.
LiSJHwangHFYuWYLinMR.Potentially inappropriate medication use, polypharmacy, and falls among hospitalized patients. Geriatr Gerontol Int. 2022;22(10):857-864. doi:10.1111/ggi.14473
21.
VentolaCL.Big data and pharmacovigilance: data mining for adverse drug events and interactions. P T. 2018;43(6):340-351.
BandaJMEvansLVanguriRSTatonettiNPRyanPBShahNH.Data descriptor: a curated and standardized adverse drug event resource to accelerate drug safety research. Scientific Data. 2016;3:1-11. doi:10.1038/sdata.2016.26
TieuCBrederCD.A critical evaluation of safety signal analysis using algorithmic standardised MedDRA queries. Drug Saf. 2018;41(12):1375-1385. doi:10.1007/s40264-018-0706-7
28.
RothmanKJLanesSSacksST.The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf. 2004;13(8):519-523. doi:10.1002/pds.1001
29.
MontastrucJLSommetABagheriHLapeyre-MestreM.Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database: commentary. Br J Clin Pharmacol. 2011;72(6):905-908. doi:10.1111/j.1365-2125.2011.04037.x
IbrahimHAbdoAEl KerdawyAMEldinAS.Signal detection in pharmacovigilance: a review of informatics-driven approaches for the discovery of drug-drug interaction signals in different data sources. Artif Int Life Sci. 2021;1:100005. doi:10.1016/j.ailsci.2021.100005
32.
KimHRSungMParkJA, et al. Analyzing adverse drug reaction using statistical and machine learning methods: a systematic review. Medicine. 2022;101(25):e29387. doi:10.1097/MD.0000000000029387
33.
NorénGNHopstadiusJBateA.Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57-69. doi:10.1177/0962280211403604
34.
Villa ZapataLHanstenPDHornJR, et al. Evidence of clinically meaningful drug–drug interaction with concomitant use of colchicine and clarithromycin. Drug Saf. 2020;43(7):661-668. doi:10.1007/s40264-020-00930-7
35.
JödickeAMCurkovicIZellwegerU, et al. Analysis of drug-drug interactions in Swiss claims data using tizanidine and ciprofloxacin as a prototypical contraindicated combination. Ann Pharmacother. 2018;52(10):983-991. doi:10.1177/1060028018775914
36.
YuanJShenCWangCShenGHanB.Assessment of physician’s knowledge of potential drug-drug interactions: an online survey in China. Front Med (Lausanne). 2021;8:650369. doi:10.3389/fmed.2021.650369
37.
KoYMaloneDCSkrepnekGH, et al. Prescribers’ knowledge of and sources of information for potential drug-drug interactions: a postal survey of US prescribers. Drug Saf. 2008;31(6):525-536. doi:10.2165/00002018-200831060-00007
38.
WrightAMcEvoyDSAaronS, et al. Structured override reasons for drug-drug interaction alerts in electronic health records. J Am Med Inform Assoc. 2019;26(10):934-942. doi:10.1093/jamia/ocz033
LeungYYYao HuiLLKrausVB.Colchicine—update on mechanisms of action and therapeutic uses. Semin Arthritis Rheum. 2015;45(3):341-350. doi:10.1016/j.semarthrit.2015.06.013
de KanterCTKeuterMvan der LeeMJKoopmansPPBurgerDM.Rhabdomyolysis in an HIV-infected patient with impaired renal function concomitantly treated with rosuvastatin and lopinavir/ritonavir. Antivir Ther. 2011;16(3):435-437. doi:10.3851/IMP1747
47.
MikhailNIskanderECopeD.Rhabdomyolysis in an HIV-infected patient on anti-retroviral therapy precipitated by high-dose pravastatin. Curr Drug Saf. 2009;4(2):121-122. doi:10.2174/157488609788173080
48.
HarpazRChaseHSFriedmanC.Mining multi-item drug adverse effect associations in spontaneous reporting systems. BMC Bioinformatics. 2010;11(suppl 7):S9. doi:10.1186/1471-2105-11-S9-S7
49.
HazellLShakirSAW. Under-reporting of adverse drug reactions: a systematic review. Drug Safety. 2006;29(5):385-396. doi:10.2165/00002018-200629050-00003
50.
AveryAJAndersonCBondCM, et al. Evaluation of patient reporting of adverse drug reactions to the UK “Yellow card scheme”: literature review, descriptive and qualitative analyses, and questionnaire surveys. Health Technol Assess. 2011;15(20):1-234, iii-iv.
51.
AlatawiYMHansenRA.Empirical estimation of under-reporting in the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). Expert Opin Drug Saf. 2017;16(7):761-767. doi:10.1080/14740338.2017.1323867
52.
PalleriaCLeporiniCChimirriS, et al. Limitations and obstacles of the spontaneous adverse drugs reactions reporting: two “challenging” case reports. J Pharmacol Pharmacother. 2013;4(suppl 1):S66-S72. doi:10.4103/0976-500X.120955
53.
AmanovaAKendi CelebiZBakarFCaglayanMGKevenK.Colchicine levels in chronic kidney diseases and kidney transplant recipients using tacrolimus. Clin Transplant. 2014;28(10):1177-1183. doi:10.1111/ctr.12448
